Researchers report an improvement in the language ability of Alzheimer’s patients by using a new immune-based approach to treatment.
The study, published in the open access journal BMC Neurology, demonstrates rapid language improvement in patients with Alzheimer’s disease within minutes of using the novel treatment.
Continuing on from previous work, the authors focused on the effect of the anti-tumor necrosis factor–alpha (TNF-alpha) drug, etanercept, on measures of verbal ability.
By utilizing a unique perispinal delivery method to administer etanercept, the researchers aimed to reduce elevated levels of TNF-alpha in the brain.
Commenting on the findings, lead author of the report, Edward Tobinick, said: "There are limitations to the data presented; the clinical trial was open label, and not controlled. These caveats notwithstanding, the scientific rationale for the further investigation of anti-TNF-alpha treatment of Alzheimer’s disease is compelling.
"In addition, family members, independent neurologists, and other independent observers have confirmed the clinical, cognitive, and behavioral improvement noted."
According to the Alzheimer’s Association, there are an estimated 5.2 million Americans living with the disease, and this number is expected to grow to as many as 16 million by 2050.
